Weekly dosage of docetaxel for patients with advanced non-small-cell lung cancer and breast cancer

Objective: To evaluate the therapeutic effect and side effect of weekly docetaxel in patients with advanced non-small-cell lung cancer and breast cancer.Methods: Thirty-six patients with advanced non-small-cell lung cancer and breast cancer received weekly docetaxel(25-40 mg/m² on Day1,8,15 every 4 weeks) in combination with cisplatin or with cisplatin or capecitabine or epirubicin.Results: All the therapeutic effects and toxicities were evaluated by WHO standard.Complete response was observed in 3 cases,partial response in 10 cases,stable disease in 9 cases and progressive disease in 12 cases,with a total response rate of 36.1%.The main toxicity reaction was mild hematological toxicities.The incidence of leukopenia was 25.0% and that of grade III leucopenia 6.0%.The incidence rate of grade 1 to 2 anemia was 5.0%.Other non-hematological toxicities were rarely seen.Conclusions: Weekly docetaxel is safe and effect for treatment of patients with advanced breast cancer or non-small-cell lung cancer.